Investigate / CRL
Understand CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Can improving client spending and cost-saving actions offset demand uncertainty and execution risk across its three segments?
Snapshot reviewed 2026-10-02. Source published 2026-08-05. No account needed.
AI-assisted synthesis of selected public filings, checked against the cited excerpts. Not a complete analysis.
This is a research starting point, not a buy/sell recommendation or a current valuation. New developments after these sources are not incorporated automatically.
Ownership-page coverage is not available for this company. That does not mean no tracked investor owns it.
Your research workspace / CRL
Ask better questions. Keep the evidence.
Explore the available sources for CHARLES RIVER LABORATORIES INTERNATIONAL, INC., then keep what deserves another look.
01 Investor activity
Ownership coverage is unavailable—not zero owners.
02 Business evidence
Reported evidence
What does the company do?
Charles River provides research models and discovery, safety assessment and manufacturing-support products and services that help clients carry out non-clinical drug development, from target identification onward.
Latticework interpretation
What could support the case?
If improving client spending continues and the backlog holds up, demand for Discovery and Safety Assessment services could stabilize, though the filing describes the environment as cautious.
Latticework interpretation
What could break the case?
If contracts are terminated, reduced in scope, underpriced or subject to cost overruns and delays, Charles River could bear the resulting financial risk.
03 Questions to investigate
Open saved takeaways →Read the full company brief
1. Understand the business
Charles River provides research models and discovery, safety assessment and manufacturing-support products and services that help clients carry out non-clinical drug development, from target identification onward.
Source: Latest filing · business description ↗2. What the reported results show
Latest source: 10-Q, reporting period ended 2026-06-27. Selected reported US-GAAP/USD comparisons. The period and basis of each measure are shown separately; year-to-date cash flow is not a quarterly figure. Missing comparisons are collection gaps, not evidence that a company has no revenue or earnings.
| Measure | Current | Prior year |
|---|---|---|
| Revenue from customer contracts ↗Quarter: 2026-03-29–2026-06-27; prior 2025-03-30–2025-06-28Both values reported in the current filing. Excludes assessed tax; this concept may exclude other company revenue. | $1,004.078m | $1,032.135m |
| Operating income ↗Quarter: 2026-03-29–2026-06-27; prior 2025-03-30–2025-06-28Both values reported in the current filing. | $119.888m | $100.134m |
| Net income ↗Quarter: 2026-03-29–2026-06-27; prior 2025-03-30–2025-06-28Both values reported in the current filing. | −$1.482m | $52.326m |
| Operating cash flow ↗Six months (year to date): 2025-12-28–2026-06-27; prior 2024-12-29–2025-06-28Both values reported in the current filing. Operating cash flow is not free cash flow or a standalone solvency assessment; inspect the full statement. | $220.802m | $376.3m |
Comparison caveat: Current net income includes a loss on the CDMO and Cell Solutions divestiture, while the business scope also changed. The net-income decline is not solely an operating-demand comparison.
10-Q · latest checked financial statements and discussion ↗3. The investment debate
Latticework interpretation of the reported results—not the stated motives of any investor.
What could support the case
If improving client spending continues and the backlog holds up, demand for Discovery and Safety Assessment services could stabilize, though the filing describes the environment as cautious.
Supporting filing ↗The strongest caution
If contracts are terminated, reduced in scope, underpriced or subject to cost overruns and delays, Charles River could bear the resulting financial risk.
Caution evidence ↗An interesting business is not necessarily an attractive investment at today's price. Price, dilution, financing terms and a valuation range still need investigation.
Inspect the evidence behind both sides ↗4. Three questions worth investigating
Use these to guide your research, not as conclusions that have already been proved.
Do cost savings materialize?
Starting evidence: Failure to realize intended restructuring savings could adversely affect the business; the savings should not be treated as already achieved.
Investigate next: Compare management's stated savings targets with reported margins and restructuring charges in later filings.
Read the supporting filing ↗How will the recent divestitures change the business?
Starting evidence: Charles River sold certain European Discovery Services and its CDMO and Cell Solutions businesses, changing the scope of its segments.
Investigate next: Review segment disclosures and guidance to see how the sold units affected segment scope and results.
Read the supporting filing ↗Is demand for outsourced non-clinical work durable?
Starting evidence: The risk factors state the outsourcing trend in non-clinical and clinical drug development could decrease, which could impair growth.
Investigate next: Track backlog, client spending commentary and cancellation or delay disclosures across reporting periods.
Read the supporting filing ↗5. Decide what to do next
Worth another look? Save this company and return to the evidence. Writing a private view is optional. You do not need to decide whether to invest today.
Save is on this device. Recording a private view requires sign-in and an explicit save. Neither action subscribes you to email or automatically evaluates your thesis.